Advertisement
| cns healthcare depression study: Transforming Clinical Research in the United States Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, 2010-10-22 An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise. |
| cns healthcare depression study: Animal and Translational Models for CNS Drug Discovery: Neurological Disorders Robert A. McArthur, Franco Borsini, 2008-11-18 Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer's disease, Parkinson's disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually. - Clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process - Critical evaluation of animal and translational models improving transition from drug discovery and clinical development - Emphasis on what results mean to the overall drug discovery process - Exploration of issues in clinical trial design and conductance in each therapeutic area |
| cns healthcare depression study: Sleep Disorders and Sleep Deprivation Institute of Medicine, Board on Health Sciences Policy, Committee on Sleep Medicine and Research, 2006-10-13 Clinical practice related to sleep problems and sleep disorders has been expanding rapidly in the last few years, but scientific research is not keeping pace. Sleep apnea, insomnia, and restless legs syndrome are three examples of very common disorders for which we have little biological information. This new book cuts across a variety of medical disciplines such as neurology, pulmonology, pediatrics, internal medicine, psychiatry, psychology, otolaryngology, and nursing, as well as other medical practices with an interest in the management of sleep pathology. This area of research is not limited to very young and old patientsâ€sleep disorders reach across all ages and ethnicities. Sleep Disorders and Sleep Deprivation presents a structured analysis that explores the following: Improving awareness among the general public and health care professionals. Increasing investment in interdisciplinary somnology and sleep medicine research training and mentoring activities. Validating and developing new and existing technologies for diagnosis and treatment. This book will be of interest to those looking to learn more about the enormous public health burden of sleep disorders and sleep deprivation and the strikingly limited capacity of the health care enterprise to identify and treat the majority of individuals suffering from sleep problems. |
| cns healthcare depression study: The Role of Protein and Amino Acids in Sustaining and Enhancing Performance Institute of Medicine, Committee on Military Nutrition Research, 1999-09-15 It is a commonly held belief that athletes, particularly body builders, have greater requirements for dietary protein than sedentary individuals. However, the evidence in support of this contention is controversial. This book is the latest in a series of publications designed to inform both civilian and military scientists and personnel about issues related to nutrition and military service. Among the many other stressors they experience, soldiers face unique nutritional demands during combat. Of particular concern is the role that dietary protein might play in controlling muscle mass and strength, response to injury and infection, and cognitive performance. The first part of the book contains the committee's summary of the workshop, responses to the Army's questions, conclusions, and recommendations. The remainder of the book contains papers contributed by speakers at the workshop on such topics as, the effects of aging and hormones on regulation of muscle mass and function, alterations in protein metabolism due to the stress of injury or infection, the role of individual amino acids, the components of proteins, as neurotransmitters, hormones, and modulators of various physiological processes, and the efficacy and safety considerations associated with dietary supplements aimed at enhancing performance. |
| cns healthcare depression study: Lipid Metabolism and Transport in CNS Health and Disease Kimberley D. Bruce, Alfred N. Fonteh, Hussein N. Yassine, 2021-12-07 |
| cns healthcare depression study: Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics Carl Faingold, Hal Blumenfeld, 2013-12-26 Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics, edited by two leaders in the field, offers a current and complete review of what we know about neural networks. How the brain accomplishes many of its more complex tasks can only be understood via study of neuronal network control and network interactions. Large networks can undergo major functional changes, resulting in substantially different brain function and affecting everything from learning to the potential for epilepsy. With chapters authored by experts in each topic, this book advances the understanding of: - How the brain carries out important tasks via networks - How these networks interact in normal brain function - Major mechanisms that control network function - The interaction of the normal networks to produce more complex behaviors - How brain disorders can result from abnormal interactions - How therapy of disorders can be advanced through this network approach This book will benefit neuroscience researchers and graduate students with an interest in networks, as well as clinicians in neuroscience, pharmacology, and psychiatry dealing with neurobiological disorders. - Utilizes perspectives and tools from various neuroscience subdisciplines (cellular, systems, physiologic), making the volume broadly relevant - Chapters explore normal network function and control mechanisms, with an eye to improving therapies for brain disorders - Reflects predominant disciplinary shift from an anatomical to a functional perspective of the brain - Edited work with chapters authored by leaders in the field around the globe – the broadest, most expert coverage available |
| cns healthcare depression study: Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (ADHD). , 1998 |
| cns healthcare depression study: DSM-5 Classification American Psychiatric Association, 2015-08-25 This handy DSM-5(R) Classification provides a ready reference to the DSM-5 classification of disorders, as well as the DSM-5 listings of ICD-9-CM and ICD-10-CM codes for all DSM-5 diagnoses. To be used in tandem with DSM-5(R) or the Desk Reference to the Diagnostic Criteria From DSM-5(R), the DSM-5(R) Classification makes accessing the proper diagnostic codes quick and convenient. With the advent of ICD-10-CM implementation in the United States on October 1, 2015, this resource provides quick access to the following: - The DSM-5(R) classification of disorders, presented in the same sequence as in DSM-5(R), with both ICD-9-CM and ICD-10-CM codes. All subtypes and specifiers for each DSM-5(R) disorder are included.- An alphabetical listing of all DSM-5 diagnoses with their associated ICD-9-CM and ICD-10-CM codes.- Separate numerical listings according to the ICD-9-CM codes and the ICD-10-CM codes for each DSM-5(R) diagnosis.- For all listings, any codable subtypes and specifiers are included with their corresponding ICD-9-CM or ICD-10-CM codes, if applicable. The easy-to-use format will prove indispensable to a diverse audience--for example, clinicians in a variety of fields, including psychiatry, primary care medicine, and psychology; coders working in medical centers and clinics; insurance companies processing benefit claims; individuals conducting utilization or quality assurance reviews of specific cases; and community mental health organizations at the state or county level. |
| cns healthcare depression study: Beyond the HIPAA Privacy Rule Institute of Medicine, Board on Health Care Services, Board on Health Sciences Policy, Committee on Health Research and the Privacy of Health Information: The HIPAA Privacy Rule, 2009-03-24 In the realm of health care, privacy protections are needed to preserve patients' dignity and prevent possible harms. Ten years ago, to address these concerns as well as set guidelines for ethical health research, Congress called for a set of federal standards now known as the HIPAA Privacy Rule. In its 2009 report, Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research, the Institute of Medicine's Committee on Health Research and the Privacy of Health Information concludes that the HIPAA Privacy Rule does not protect privacy as well as it should, and that it impedes important health research. |
| cns healthcare depression study: The Biopsychosocial Model of Health and Disease Derek Bolton, Grant Gillett, 2019-03-28 This open access book is a systematic update of the philosophical and scientific foundations of the biopsychosocial model of health, disease and healthcare. First proposed by George Engel 40 years ago, the Biopsychosocial Model is much cited in healthcare settings worldwide, but has been increasingly criticised for being vague, lacking in content, and in need of reworking in the light of recent developments. The book confronts the rapid changes to psychological science, neuroscience, healthcare, and philosophy that have occurred since the model was first proposed and addresses key issues such as the model’s scientific basis, clinical utility, and philosophical coherence. The authors conceptualise biology and the psychosocial as in the same ontological space, interlinked by systems of communication-based regulatory control which constitute a new kind of causation. These are distinguished from physical and chemical laws, most clearly because they can break down, thus providing the basis for difference between health and disease. This work offers an urgent update to the model’s scientific and philosophical foundations, providing a new and coherent account of causal interactions between the biological, the psychological and social. |
| cns healthcare depression study: Charney & Nestler's Neurobiology of Mental Illness Dennis S. Charney, Pamela B. Sklar, Eric J. Nestler, Joseph D. Buxbaum, 2018 In the years following publication of the DSM-5(R), the field of psychiatry has seen vigorous debate between the DSM's more traditional, diagnosis-oriented approach and the NIMH's more biological, dimension-based RDoC (research domain criteria) approach. Charney & Nestler's Neurobiology of Mental Illness is an authoritative foundation for translating information from the laboratory to clinical treatment, and its fifth edition extends beyond this reference function to acknowledge and examine the controversies, different camps, and thoughts on the future of psychiatric diagnosis. In this wider context, this book provides information from numerous levels of analysis, including molecular biology and genetics, cellular physiology, neuroanatomy, neuropharmacology, epidemiology, and behavior. Sections and chapters are edited and authored by experts at the top of their fields. No other book distills the basic science and underpinnings of mental disorders-and highlights practical clinical significance-to the scope and breadth of this classic text. In this edition, Section 1, which reviews the methods used to examine the biological basis of mental illness in animal and cell models and in humans, has been expanded to reflect critically important technical advances in complex genetics (including powerful sequencing technologies and related bioinformatics), epigenetics, stem cell biology, optogenetics, neural circuit functioning, cognitive neuroscience, and brain imaging. This range of established and emerging methodologies offer groundbreaking advances in our ability to study the brain as well as unique opportunities for the translation of preclinical and clinical research into badly needed breakthroughs in our therapeutic toolkit. Sections 2 through 7 cover the neurobiology and genetics of major psychiatric disorders: psychoses (including bipolar disorder), mood disorders, anxiety disorders, substance use disorders, dementias, and disorders of childhood onset. Also covered within these sections is a summary of current therapeutic approaches for these illnesses as well as the ways in which research advances are now guiding the search for new treatments. Each of these parts has been augmented in several different areas as a reflection of research progress. The last section, Section 8, reconfigured in this new edition, now focuses on diagnostic schemes for mental illness. This includes an overview of the unique challenges that remain in diagnosing these disorders given our still limited knowledge of disease etiology and pathophysiology. The section then provides reviews of DSM-5(R), which forms the basis of psychiatric diagnosis in the United States for all clinical work, and of RDoC, which provides an alternative perspective on diagnosis in heavy use in the research community. Also included are chapters on future efforts toward precision and computational psychiatry, which promise to someday align diagnosis with underlying biological abnormalities. |
| cns healthcare depression study: Comorbidity of Mental and Physical Disorders N. Sartorius, R.I.G. Holt, M. Maj, 2014-11-26 This publication presents evidence about the magnitude and severe consequences of comorbidity of mental and physical illnesses from a personal and societal perspective. Leading experts address the huge burden of co-morbidity to the affected individual as well as the public health aspects, the costs to society and interaction with factors stemming from the context of socioeconomic developments. The authors discuss the clinical challenge of managing cardiovascular illnesses, cancer, infectious diseases and other physical illness when they occur with a range of mental and behavioral disorders, including substance abuse, eating disorders and anxiety. Also covered are the organization of health services, the training of different categories of health personnel and the multidisciplinary engagement necessary to prevent and manage comorbidity effectively. The book is essential reading for general practitioners, internists, public health specialists, psychiatrists, cardiologists, oncologists, medical educationalists and other health care professionals. |
| cns healthcare depression study: Cognitive Dimensions of Major Depressive Disorder Bernhard T. Baune, Catherine Harmer, 2019 This unique guide enhances readers understanding of the dimensional approach of depression by focusing on the cognitive, emotional, and social cognitive processes. |
| cns healthcare depression study: Ketamine for Treatment-Resistant Depression Sanjay J. Mathew, Carlos A. Zarate, Jr., 2016-11-25 This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research. |
| cns healthcare depression study: Depression: New Insights for the Healthcare Professional: 2013 Edition , 2013-07-22 Depression: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Depression: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Depression: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| cns healthcare depression study: Versed Rae Armantrout, 2010-08 A collection of poetry organized in two sections. The first section, Versed, play with vice and versa, the perversity of human consciousness. They flirt with error and delusion, skating on a thin ice that inevitably cracks. The second section, Dark Matter, alludes to more than the unseen substance thought to make up the majority of mass in the universe. The invisible and unknowable are confronted directly as the author's experience with cancer marks these poems with a new austerity, shot through with her signature wit and stark unsentimental thinking.--Résumé de l'éditeur. |
| cns healthcare depression study: Drug-Induced Liver Injury , 2019-07-13 Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series |
| cns healthcare depression study: Natural Medications for Psychiatric Disorders David Mischoulon, Jerrold F. Rosenbaum, 2008 Updated for its Second Edition, this book is the only reference to focus exclusively on natural medications in psychiatry. Eminent psychiatrists from the Massachusetts General Hospital and other leading institutions examine current scientific and clinical data on the applications, effectiveness, and safety of natural psychotropics and acupuncture. Quick-reference tabular appendices list indications, contraindications, dosages, combinations, and drug-drug interactions for each remedy. This edition includes brand-new chapters on acupuncture, homeopathy, and therapies for substance dependence and weight management. The chapter on polypharmacy and side effect management addresses the growing issue of drug-drug interactions. New introductory chapters discuss complementary and alternative medicine in society and examine research limitations and quality assurance issues. |
| cns healthcare depression study: Cognitive Impairment in Major Depressive Disorder Roger S. McIntyre, Danielle S. Cha, 2016-03-17 The first book to comprehensively assemble research, clinical, and public policy perspectives on cognitive dysfunction in major depressive disorder. |
| cns healthcare depression study: Depression and Heart Disease Alexander Glassman, Mario M. Maj, Norman Sartorius, 2011-06-20 Recently, there has been a growing awareness of the multiple interrelationships between depression and various physical diseases. Patients with psychiatric problems, particularly depression, may be more susceptible to cardiovascular disorders. Depression and Heart Disease synthesizes current evidence, including some previously unpublished data, in a concise, easy-to-read format. The authors succinctly describe the epidemiology, pathogenesis (including cytokines and genetics), and risk factors of the comorbidity between depression and heart disease. The book also reviews the best pharmacological and psychotherapeutic approaches for people with this comorbidity. |
| cns healthcare depression study: Pituitary Adenylate Cyclase-Activating Polypeptide Hubert Vaudry, Akira Arimura, 2003 Pituitary Adenylate Cyclase-Activating Polypeptide is the first volume to be written on the neuropeptide PACAP. It covers all domains of PACAP from molecular and cellular aspects to physiological activities and promises for new therapeutic strategies. Pituitary Adenylate Cyclase-Activating Polypeptide is the twentieth volume published in the Endocrine Updates book series under the Series Editorship of Shlomo Melmed, MD. |
| cns healthcare depression study: Fluoxetine Graziano Pinna, 2015-04-01 Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure. |
| cns healthcare depression study: Clinical Recovery from CNS Damage Hiroaki Naritomi, D. W. Krieger, 2013 A compilation of innovative findings and new directions in neurological recovery After decades of focusing on how to alleviate and prevent recurrence of acute CNS injuries, the emphasis has finally shifted towards repairing such devastating events and rehabilitation. This development has been made possible by substantial progress in understanding the scientific underpinnings of recovery as well as by novel diagnostic tools, and most importantly, by emerging therapies awaiting clinical trials. In this publication, several international experts introduce novel areas of neurological reorganization and repair following CNS damage. Principles and methods to monitor and augment neuroplasticity are explored in depth and supplemented by a critical appraisal of neurological repair mechanisms and possibilities to curtail disability using computer or robotic interfaces. Rather than providing a textbook approach of CNS restoration, the editors selected topics where progress is most imminent in this labyrinthine domain of medicine. Moreover, the varied background and origins of the contributors lend this book a truly global perspective on the current state of affairs in neurological recovery. |
| cns healthcare depression study: Neurocognitive disorders and depression – complex interrelationships Katarzyna Milana Broczek, Marie-Christine Gely-Nargeot, Pietro Gareri, 2023-03-02 |
| cns healthcare depression study: Public Health Perspectives on Depressive Disorders Neal L. Cohen, 2017-08-29 How does mental health impact public health? In 2001, the WHO recognized depressive disorders as the leading cause of disability worldwide. But most Americans who meet diagnostic criteria for major depression are untreated or undertreated. Luckily, recent advances have finally made it possible for the field of public health to address mental health in the population. Public Health Perspectives on Depressive Disorders fills a gap by identifying the tools and strategies of public health practice and by exploring their application to twenty-first-century public mental health policy and practice. By looking at depressive disorders through a public health lens, this book highlights the centrality of mental health to public health. Linking the available research on depressive illness at the population level with public mental health policy and practice, expert contributors set a research agenda that will help make mental health a central part of public health science and practice. This book is an invaluable resource for researchers and practitioners to develop, facilitate, and conduct pilot and feasibility studies of promising preventive and treatment interventions that might mitigate the progression toward major depression and other mental disorders among populations at risk. The first part of the book underscores the public health significance of depressive illness by focusing on the evidence provided by recent approaches to nosology, epidemiology, illness burden, and impact on overall health. The second part looks at the social and environmental influences on depressive disorders that are critical to future efforts to prevent illness and to promote mentally healthy communities. The third and longest part addresses the vulnerability of diverse groups to depressive illness and underscore best practices to mitigate risk while improving both the preventive and therapeutic armamentaria. |
| cns healthcare depression study: Brain Plasticity and Behavior Bryan Kolb, 1995 First Published in 1995. Routledge is an imprint of Taylor & Francis, an informa company. |
| cns healthcare depression study: Stress Challenges and Immunity in Space Alexander Choukèr, 2020-12-03 This book explains how stress – either psychological or physical – can activate and/or paralyse human innate or adaptive immunity. Adequate immunity is crucial for maintaining health, both on Earth and in space. During space flight, human physiology is specifically challenged by complex environmental stressors, which are most pronounced during lunar or interplanetary missions. Adopting an interdisciplinary approach, the book identifies the impact of these stressors – the space exposome – on immunity as a result of (dys-)functions of specific cells, organs and organ networks. These conditions (e.g. gravitation changes, radiation, isolation/confinement) affect immunity, but at the same time provide insights that may help to prevent, diagnose and address immune-related health alterations. Written by experts from academia, space agencies and industry, the book is a valuable resource for professionals, researchers and students in the field of medicine, biology and technology. The chapters “The Impact of Everyday Stressors on the Immune System and Health”, “Stress and Radiation Responsiveness” and “Assessment of Radiosensitivity and Biomonitoring of Exposure to Space adiation” are available open access under a Creative Commons Attribution 4.0 International License via link.springer.com. |
| cns healthcare depression study: Tasman’s Psychiatry Allan Tasman, Michelle B. Riba, Renato D. Alarcón, César A. Alfonso, Shigenobu Kanba, Dusica Lecic-Tosevski, David M. Ndetei, Chee H. Ng, Thomas G. Schulze, 2024-09-30 Authored by over 500 internationally acclaimed expert editors and chapter authors from around the world. Completely updated and expanded with almost 40 new chapters. Significantly increased attention to the role of culture in all aspects of evaluation and care. New sections on Digital Mental Health Services and Technologies, Treatment Issues in Specific Populations and Settings, and on Prevention, Systems of Care, and Psychosocial Aspects of Treatment address key advances. This edition is the first comprehensive reference work to cover the entire field of psychiatry in an updateable format, ensuring access to state of the art information. Earlier editions were called “the best current textbook of psychiatry” by the New England Journal of Medicine, and “the gold standard” by the American Journal of Psychiatry. Tasman’s Psychiatry, 5th Edition, builds on the initial vision in prior editions of approaching psychiatric evaluation and care from an integrative bio-psycho-social-cultural perspective. It is designed to be an essential and accessible reference for readers at any level of experience. This editorial approach encompasses the importance of the first encounter between patient and clinician, followed by the complex task of beginning to develop a therapeutic relationship and to develop and implement a treatment plan in collaboration with the patient. The importance of increasing attention to the role of culture and social determinants of mental health is reflected both in specific chapters and in components of many chapters throughout the book, especially in those pertaining to clinical evaluation, the therapeutic alliance, and treatment. The global scope of this edition is reflected throughout the book, including the section on psychiatric disorders where evaluation using both ICD 11 and DSM 5-TR is discussed. Most chapters are authored by experts from at least two different countries or continents, adding a critically important dimension which often is missing in major psychiatric textbooks. Tasman’s Psychiatry, 5th Edition, is an essential reference for all medical professionals and students who need a trusted reference or learning tool for psychiatry, psychology, clinical research, social work, counseling, therapy, and all others. |
| cns healthcare depression study: The Psychobiotic Revolution Scott C Anderson, John F. Cryan, Ted Dinan, 2017-11-30 A friendly, interesting, and up-to-date read on the science of the microbiome and the brain - Psychology Today Compelling, engaging, and informative, this book teaches us why microbes may affect all of our decisions - Jack Gilbert Ph.D., co-author of Dirt Is Good MEET YOUR MICROBES Written by the leading researchers in the field, this information-rich guide to improving your mood explains how gut health drives psychological well-being, and how depression and anxiety can be relieved by adjusting your intestinal bacteria. This groundbreaking book explains the revolutionary new science of psychobiotics and the discovery that your brain health and state of mind are intimately connected to your microbiome, that four-pound population of microbes living inside your intestines. Leading medical researchers John F. Cryan and Ted Dinan, working with veteran journalist Scott C. Anderson, explain how common mental health problems, particularly depression and anxiety, can be improved by caring for the intestinal microbiome. Science is proving that a healthy gut means a healthy mind -- and this book details the steps you can take to change your mood and improve your life by nurturing your microbiome. |
| cns healthcare depression study: The End of Trauma George A. Bonanno, 2021-09-07 With “groundbreaking research on the psychology of resilience” (Adam Grant), a top expert on human trauma argues that we vastly overestimate how common PTSD is in and fail to recognize how resilient people really are. After 9/11, mental health professionals flocked to New York to handle what everyone assumed would be a flood of trauma cases. Oddly, the flood never came. In The End of Trauma, pioneering psychologist George A. Bonanno argues that we failed to predict the psychological response to 9/11 because most of what we understand about trauma is wrong. For starters, it’s not nearly as common as we think. In fact, people are overwhelmingly resilient to adversity. What we often interpret as PTSD are signs of a natural process of learning how to deal with a specific situation. We can cope far more effectively if we understand how this process works. Drawing on four decades of research, Bonanno explains what makes us resilient, why we sometimes aren’t, and how we can better handle traumatic stress. Hopeful and humane, The End of Trauma overturns everything we thought we knew about how people respond to hardship. |
| cns healthcare depression study: Mental Health for Emergency Departments , 2009 |
| cns healthcare depression study: The Relaxation Response Herbert Benson, M.D., Miriam Z. Klipper, 2009-09-22 In this time of quarantine and global uncertainty, it can be difficult to deal with the increased stress and anxiety. Using ancient self-care techniques rediscovered by Herbert Benson, M.D., a pioneer in mind/body medicine for health and wellness, you can relieve your stress, anxiety, and depression at home with just ten minutes a day. Herbert Benson, M.D., first wrote about a simple, effective mind/body approach to lowering blood pressure in The Relaxation Response. When Dr. Benson introduced this approach to relieving stress over forty years ago, his book became an instant national bestseller, which has sold over six million copies. Since that time, millions of people have learned the secret—without high-priced lectures or prescription medicines. The Relaxation Response has become the classic reference recommended by most health care professionals and authorities to treat the harmful effects of stress, anxiety, depression, and high blood pressure. Rediscovered by Dr. Benson and his colleagues in the laboratories of Harvard Medical School and its teaching hospitals, this revitalizing, therapeutic tack is now routinely recommended to treat patients suffering from stress and anxiety, including heart conditions, high blood pressure, chronic pain, insomnia, and many other physical and psychological ailments. It requires only minutes to learn, and just ten minutes of practice a day. |
| cns healthcare depression study: Recent Advances in Biological Psychiatry Joseph Wortis, 2014-09-01 |
| cns healthcare depression study: Report of the Surgeon General's Conference on Children's Mental Health United States. Public Health Service. Office of the Surgeon General, 2000 Conference held Sept. 18-19, 2000, Washington, DC. The purpose of the conference was to engage a group of citizens in a thoughtful, meaningful dialogue about issues of prevention, identification, recognition, and referral of children with mental health needs to appropriate, evidence-based treatments or services. |
| cns healthcare depression study: The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia American Psychiatric Association, 2016 The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. |
| cns healthcare depression study: Biomedical Index to PHS-supported Research: pt. A. Subject access A-H , 1992 |
| cns healthcare depression study: The Prescriber's Guide, Antidepressants Stephen M. Stahl, 2009-04-27 This is a spin-off from Stephen M. Stahl's new, completely revised and updated version of his much-acclaimed Prescriber's Guide, covering drugs to treat depression. |
| cns healthcare depression study: Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease Mark Lyte, John F. Cryan, 2014-07-05 The field of microbial endocrinology is expressly devoted to understanding the mechanisms by which the microbiota (bacteria within the microbiome) interact with the host (“us”). This interaction is a two-way street and the driving force that governs these interactions are the neuroendocrine products of both the host and the microbiota. Chapters include neuroendocrine hormone-induced changes in gene expression and microbial endocrinology and probiotics. This is the first in a series of books dedicated to understanding how bi-directional communication between host and bacteria represents the cutting edge of translational medical research, and hopefully identifies new ways to understand the mechanisms that determine health and disease. |
| cns healthcare depression study: Urban Mental Health Dinesh Bhugra, Antonio Ventriglio, Layla McCay, Joao Castaldelli-Maia, 2019 Edited by pioneers in social psychiatry and cultural psychiatry, this resource discusses the challenges of managing mental health and psychiatric disorders in urban areas. |
| cns healthcare depression study: New Antiepileptic Drugs Francesco Pisani, 1991 The pharmacological fight against epilepsy began many centuries ago when Hippocrates discovered that the cause of epilepsy is natural, as opposed to supernatural and, as a consequence, must be treated with a natural remedy. Even though science has significantly progressed since that era, the challenge to find remedies for epilepsy is ever present. The aim of this particular volume is to offer an up-to-date review of the most recent advances in antiepileptic drug development, considered from various viewpoints: (i) general, by taking into account the size of refractory epilepsy and its related problems; (ii) experimental, by exploring the mechanisms of epileptogenesis and the possiblility of influencing it through drugs, and (iii) clinical, by describing the results obtained with compounds currently at an advanced stage of testing. |
How to Successfully Use ClinROs in CNS Clinical Research
Outcome Assessments (COAs) used within the central nervous system (CNS) space, are challenged to meet current and forthcoming regulatory guidelines set by the FDA. As CNS …
CNS Spectrums Digital health technologies and major …
There is an urgent need to improve the clinical management of major depressive disorder (MDD), which has become increasingly prevalent over the past two decades. Several gaps and …
A Comparative Evaluation Of Central Nervous System Acting …
Drugs that stimulate or depress CNS play an important role in human therapeutics. Undesirable side effects and ineffectiveness of currently available CNS stimulants or depressants in many …
A Short Form of CNS Vital Signs for Use in Depression
The purpose of this study is to illustrate a methodology for identifying neurocognitive impairment using a short form of the CNS Vital Signs computerized testing battery. Methods Participants …
Predictors of CNS-Active Medication Use and Polypharmacy …
Depressive symptoms were assessed with the 24-item Hamilton Depression Rating Scale, and pain in-tensity was measured on an 11-point numerical rating scale. Covariates were disability …
Depression in Hospital-Employed Nurses - UNC Greensboro
Thus, the purpose of this study was to determine the prevalence of depression in a random sample of hospital-employed nurses to determine individual and workplace characteristics that …
CNS Spectrums http://journals.cambridge.org/CNS
Four focus groups were conducted with MDD patients (n 533) to elicit relevant concepts and determine whether one of several PRO scales could be used to assess cognitive symptoms of …
Caregivers’ Descriptions of Sleep Changes and Depressive …
For the purposes of this study, “sleep pattern changes” are the variations in caregivers’ normal sleep patterns that result from providing care to patients with advanced stage cancer. Chronic …
Animal models for the study of depressive disorder - Wiley …
In this paper, we reviewed the pathophysiol- ogy of the depressive disorder and its current animal models with the analysis of their transcriptomic profiles. We provide insights for selecting …
Transcranial magnetic stimulation (TMS) for major depression: …
Transcranial magnetic stimulation (TMS) is an effective and safe therapy for major depressive disorder (MDD). This study assessed quality of life (QOL) and functional status outcomes for …
CNS Spectrums Early or recent trauma in treatment-resistant …
Increasing attention has been recently devoted to treatment-resistant depression (TRD), sug-gesting it may affect from 20 to 40% of patients with major depression (MD), representing a …
CNS Spectrums Precision psychiatry and Research Domain …
In this review, we highlight the growing global interest in precision psychiatry and the potential for the National Institute of Health-devised Research Domain Criteria (RDoC) to facilitate the …
VALERIE K. ARNOLD, MD CNS HEALTHCARE OF MEMPHIS
Aug 4, 2006 · Diagnoses include ADHD, alzheimer’s disease, autism, binge eating, bipolar disorders, dementias, depressive disorders, diabetes, diabetic painful neuropathy, …
Association of Opioid and Concurrent Benzodiazepine, …
Background: Healthcare providers may be utilizing central nervous system (CNS) depressants to reduce opioid use due to recent changes in public policy. Combination use of these agents with …
Gut–brain axis: how the microbiome influences anxiety and …
Ongoing and future animal and clinical studies aimed at understanding the microbiota–gut–brain axis may provide novel approaches for prevention and treatment of mental ill-ness, including …
CNS Spectrums Early optimized pharmacological treatment in …
Early optimized pharmacological treatment in patients with depression and chronic pain. CNS Spectrums 28(2), 145 156. Major depressive disorder (MDD) is the leading cause of disability …
CNS Spectrums The relationship between peritraumatic …
Healthcare workers (HCWs) were considered a population at risk for developing psychiatric symptoms during the COVID-19 pandemic, such as anxiety, depression, and post-traumatic …
JOHN MARK JOYCE, M.D. CNS HEALTHCARE OF JACKSONVILLE
Jan 10, 2024 · Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study. CNS Spectr. …
CNS-Related Adverse Drug Reactions - askgileadmedical.com
CNS-related adverse reactions that occurred in ≥2% of participants in the BIC/FTC/TAF arm of either study included headache, abnormal dreams, dizziness, and insomnia. Any-grade …
How to Successfully Use ClinROs in CNS Clinical Research
Outcome Assessments (COAs) used within the central nervous system (CNS) space, are challenged to meet current and forthcoming regulatory guidelines set by the FDA. As CNS …
CNS SPECTRUMS
Growing evidence indicates that historical descriptions of mixed depression—broadly defined as major depressive episodes with subthreshold manic or hypomanic (hypo/manic) …
CNS Spectrums Digital health technologies and major …
There is an urgent need to improve the clinical management of major depressive disorder (MDD), which has become increasingly prevalent over the past two decades. Several gaps and …
A Comparative Evaluation Of Central Nervous System Acting …
Drugs that stimulate or depress CNS play an important role in human therapeutics. Undesirable side effects and ineffectiveness of currently available CNS stimulants or depressants in many …
A Short Form of CNS Vital Signs for Use in Depression
The purpose of this study is to illustrate a methodology for identifying neurocognitive impairment using a short form of the CNS Vital Signs computerized testing battery. Methods Participants …
Predictors of CNS-Active Medication Use and Polypharmacy …
Depressive symptoms were assessed with the 24-item Hamilton Depression Rating Scale, and pain in-tensity was measured on an 11-point numerical rating scale. Covariates were disability …
Depression in Hospital-Employed Nurses - UNC Greensboro
Thus, the purpose of this study was to determine the prevalence of depression in a random sample of hospital-employed nurses to determine individual and workplace characteristics that …
CNS Spectrums http://journals.cambridge.org/CNS
Four focus groups were conducted with MDD patients (n 533) to elicit relevant concepts and determine whether one of several PRO scales could be used to assess cognitive symptoms of …
Caregivers’ Descriptions of Sleep Changes and Depressive …
For the purposes of this study, “sleep pattern changes” are the variations in caregivers’ normal sleep patterns that result from providing care to patients with advanced stage cancer. Chronic …
Animal models for the study of depressive disorder - Wiley …
In this paper, we reviewed the pathophysiol- ogy of the depressive disorder and its current animal models with the analysis of their transcriptomic profiles. We provide insights for selecting …
Transcranial magnetic stimulation (TMS) for major …
Transcranial magnetic stimulation (TMS) is an effective and safe therapy for major depressive disorder (MDD). This study assessed quality of life (QOL) and functional status outcomes for …
CNS Spectrums Early or recent trauma in treatment-resistant …
Increasing attention has been recently devoted to treatment-resistant depression (TRD), sug-gesting it may affect from 20 to 40% of patients with major depression (MD), representing a …
CNS Spectrums Precision psychiatry and Research Domain …
In this review, we highlight the growing global interest in precision psychiatry and the potential for the National Institute of Health-devised Research Domain Criteria (RDoC) to facilitate the …
VALERIE K. ARNOLD, MD CNS HEALTHCARE OF MEMPHIS
Aug 4, 2006 · Diagnoses include ADHD, alzheimer’s disease, autism, binge eating, bipolar disorders, dementias, depressive disorders, diabetes, diabetic painful neuropathy, …
Association of Opioid and Concurrent Benzodiazepine, …
Background: Healthcare providers may be utilizing central nervous system (CNS) depressants to reduce opioid use due to recent changes in public policy. Combination use of these agents …
Gut–brain axis: how the microbiome influences anxiety and …
Ongoing and future animal and clinical studies aimed at understanding the microbiota–gut–brain axis may provide novel approaches for prevention and treatment of mental ill-ness, including …
CNS Spectrums Early optimized pharmacological treatment in …
Early optimized pharmacological treatment in patients with depression and chronic pain. CNS Spectrums 28(2), 145 156. Major depressive disorder (MDD) is the leading cause of disability …
CNS Spectrums The relationship between peritraumatic …
Healthcare workers (HCWs) were considered a population at risk for developing psychiatric symptoms during the COVID-19 pandemic, such as anxiety, depression, and post-traumatic …
JOHN MARK JOYCE, M.D. CNS HEALTHCARE OF JACKSONVILLE
Jan 10, 2024 · Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study. CNS Spectr. …
CNS-Related Adverse Drug Reactions - askgileadmedical.com
CNS-related adverse reactions that occurred in ≥2% of participants in the BIC/FTC/TAF arm of either study included headache, abnormal dreams, dizziness, and insomnia. Any-grade …
